Anemia drugs under scrutiny

Mar 13, 2008

U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.

A Food and Drug Administration advisory committee is to meet Thursday to consider eliminating the use of Amgen's drugs Epogen and Aranesp, and the Johnson & Johnson drug Procrit for cancer patients with certain types of tumors or eliminating the use among all cancer patients, The New York Times reported.

The newspaper said eight clinical trials have suggested the drugs might make tumors worse or shorten the life of cancer patients. One FDA adviser last year called the drugs "Miracle-Gro for cancer."

Researchers said the anemia drugs are synthetic forms of a human hormone called erythropoietin, or Epo, that is involved in the production of red blood cells. Epo may encourage the growth of blood vessels that nourish tumors or may actually stimulate tumors directly, scientists said. Another theory is that Epo protects tumors from being destroyed by chemotherapy.

Amgen said it has not seen any convincing evidence Epo does anything but spur red blood cell production, the newspaper said.

Copyright 2008 by United Press International

Explore further: Maker of device in 'superbug' outbreak lacked FDA clearance (Update)

add to favorites email to friend print save as pdf

Related Stories

Drug for anemic cancer patients raises risk of death

Feb 26, 2008

Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy. But a new study by Northwestern University's Feinberg School of Medicine shows these drugs, called ...

Recommended for you

FDA launches first app to identify drug shortages

2 hours ago

(HealthDay)—A mobile phone application (app) has been released to identify current drug shortages, resolved shortages, or discontinuations of drug products, according to a press release published by the ...

FDA approves first lower-cost biotech drug (Update)

4 hours ago

Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients.

A look at the growing use of synthetic drugs

5 hours ago

In recent years, hundreds of new synthetic recreational drugs have emerged – drugs that neither the general public nor the scientific community know very much about. Many of these new synthetic drugs – ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.